Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Bio-Techne (TECH) Shares Outstanding (Weighted Average) (2016 - 2021)

Historic Shares Outstanding (Weighted Average) for Bio-Techne (TECH) over the last 9 years, with Q4 2021 value amounting to $39.3 million.

  • Bio-Techne's Shares Outstanding (Weighted Average) rose 159.99% to $39.3 million in Q4 2021 from the same period last year, while for Dec 2021 it was $39.3 million, marking a year-over-year increase of 159.99%. This contributed to the annual value of $38.7 million for FY2021, which is 142.93% up from last year.
  • Bio-Techne's Shares Outstanding (Weighted Average) amounted to $39.3 million in Q4 2021, which was up 159.99% from $39.1 million recorded in Q3 2021.
  • In the past 5 years, Bio-Techne's Shares Outstanding (Weighted Average) registered a high of $39.3 million during Q4 2021, and its lowest value of $37.3 million during Q2 2017.
  • Its 5-year average for Shares Outstanding (Weighted Average) is $38.1 million, with a median of $38.0 million in 2019.
  • As far as peak fluctuations go, Bio-Techne's Shares Outstanding (Weighted Average) grew by 25.48% in 2017, and later surged by 159.99% in 2021.
  • Quarter analysis of 5 years shows Bio-Techne's Shares Outstanding (Weighted Average) stood at $37.4 million in 2017, then increased by 0.85% to $37.8 million in 2018, then rose by 1.06% to $38.2 million in 2019, then rose by 1.37% to $38.7 million in 2020, then grew by 1.6% to $39.3 million in 2021.
  • Its Shares Outstanding (Weighted Average) was $39.3 million in Q4 2021, compared to $39.1 million in Q3 2021 and $38.7 million in Q2 2021.